Accession Number:

AD1034290

Title:

A Combination Approach for Treatment of Castration-Resistant Prostate Cancer

Descriptive Note:

Technical Report,01 Sep 2015,31 Aug 2016

Corporate Author:

ADMINISTRATORS OF THE TULANE EDUCATIONAL New Orleans United States

Personal Author(s):

Report Date:

2016-09-01

Pagination or Media Count:

14.0

Abstract:

Abiraterone, enzalutamide, and taxanes are first-line treatments for metastatic castration-resistant prostate cancer mCRPC. They prolonged overall survival of the patients. However, both de novo and acquired resistance are common. Accumulating evidence has indicated a role of androgen receptor splice variants AR-Vs in mediating resistance to these therapies. The purpose of this study is to develop 20S-protopanaxadiol-aglycone PPD, which we showed to downregulate the levels and activities of AR-Vs, as an antidote to overcome resistance to these therapies. We showed that PPD might attenuate AR-V homodimerization and that combined treatment with PPD and enzalutamide might be more efficacious than enzalutamide alone in inhibiting the growth of CRPC tumors.

Subject Categories:

  • Medicine and Medical Research
  • Biochemistry
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE